Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Trial Profile

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CA-4948 (Primary)
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Curis
  • Most Recent Events

    • 06 Dec 2019 Preliminary clinical data presented in the Curis media release.
    • 05 Nov 2019 According to a Curis media release, data from this study will be presented at the upcoming 61st American Society of Hematology (ASH) Annual Meeting held December 7-10, 2019 in Orlando, FL.
    • 05 Nov 2019 According to a Curis media release, data readout from this study is expected in the fourth quarter of this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top